Pancreatic ductal adenocarcinoma (PDAC) is poised to become the second leading cause of cancer-related death by 2030, necessitating innovative therapeutic strategies. Genetic and epigenetic alterations, including those involving the COMPASS-like complex genes, have emerged as critical drivers of PDAC progression. This review explores the genetic and epigenetic landscape of PDAC, focusing on the role of the COMPASS-like complex in regulating chromatin accessibility and gene expression. Specifically, we delve into the functions of key components such as KDM6A, KMT2D, KMT2C, KMT2A, and KMT2B, highlighting their significance as potential therapeutic targets. Furthermore, we discuss the implications of these findings for developing novel treatment modalities for PDAC.
Introduction To evaluate the diagnostic performance of lung ultrasound (LUS) in detecting interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), as a radiation-free alternative to high-resolution CT (HRCT). Methods In this cross-sectional study, 18 adult participants with SSc underwent LUS and HRCT within 1 month as part of routine clinical care without previous knowledge of presence or absence of ILD. A 14-zone LUS protocol was applied and B-lines were quantified using two semiquantitative scoring systems. LUS results were compared with HRCT interpreted by a blinded thoracic radiologist. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated. Spearman correlation was used to evaluate the association between total B-line counts and HRCT severity. Results Of 18 participants, ILD was identified by HRCT in 72.2%. Using B-lines cut-off ≤5, LUS demonstrated 100% sensitivity, 40% specificity, 81% PPV and 100% NPV. Using B-lines cut-off ≤10, sensitivity was 92%, specificity 80%, PPV 92% and NPV 80%. B-line counts correlated strongly with HRCT severity (Spearman ρ=0.80, p<0.0001). Conclusion LUS shows high sensitivity and acceptable specificity for detecting ILD in SSc, particularly when using a higher B-line threshold. Future studies that incorporate LUS as an upfront screening tool are needed for validation of our findings.